Wuhan Thalys Med Tech Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.12%

Wuhan Thalys Med Tech Co Ltd (603716) has an Asset Resilience Ratio of 0.12% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥2.05 Million

≈ $299.98K USD Cash + Short-term Investments

Total Assets

CN¥1.74 Billion

≈ $254.54 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Wuhan Thalys Med Tech Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Wuhan Thalys Med Tech Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Thalys Med Tech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603716 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥2.05 Million	0.12%
Total Liquid Assets	CN¥2.05 Million	0.12%

Asset Resilience Insights

Limited Liquidity: Wuhan Thalys Med Tech Co Ltd maintains only 0.12% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Wuhan Thalys Med Tech Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Thalys Med Tech Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Cowealth Medical China Co.Ltd. SHG:603122	Diagnostics & Research	2.25%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Chemclin Diagnostics Co. Ltd. A SHG:688468	Diagnostics & Research	15.34%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%
SCOPE FLUIDICS SA ZY-10 F:S84	Diagnostics & Research	32.55%
Avricore Health Inc V:AVCR	Diagnostics & Research	1.78%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%

Annual Asset Resilience Ratio for Wuhan Thalys Med Tech Co Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Wuhan Thalys Med Tech Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.07%	CN¥1.35 Million ≈ $197.55K	CN¥1.80 Billion ≈ $263.75 Million	-0.20pp
2021-12-31	0.28%	CN¥12.00 Million ≈ $1.76 Million	CN¥4.29 Billion ≈ $628.28 Million	+0.21pp
2019-12-31	0.07%	CN¥2.00 Million ≈ $292.66K	CN¥3.01 Billion ≈ $440.03 Million	+0.03pp
2017-12-31	0.03%	CN¥500.00K ≈ $73.17K	CN¥1.57 Billion ≈ $229.65 Million	--

pp = percentage points

About Wuhan Thalys Med Tech Co Ltd

SHG:603716 China Diagnostics & Research

Market Cap

$580.19 Million

CN¥3.96 Billion CNY

Market Cap Rank

#11471 Global

#3223 in China

Share Price

CN¥17.56

Change (1 day)

+4.59%

52-Week Range

CN¥13.40 - CN¥36.40

All Time High

CN¥45.48